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1
Half of the entire heart failure (HF) population have HF with preserved ejection fraction (HF-PEF), with 
over-representation among elderly, women, and minor-
ity populations.1,2 Patients with HF-PEF have equally 
impaired health status compared with those with HF with 
reduced ejection fraction (HF-REF) because of similarly 
impaired functional capacity, signs and symptoms of HF, 
and depression.3,4 Health-related quality of life (HRQL) 
is a component of health status and will be used in this 
article for simplicity. However, no therapy has been proven 
to improve survival and hospitalizations in large clinical 
trials of HF-PEF patients,5–7 and few trials have evaluated 
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Background—Heart failure (HF) with preserved ejection fraction patients have equally impaired health-related quality of 
life (HRQL) compared with those with HF with reduced ejection fraction, but limited studies have evaluated the impact 
of therapies on changes in HRQL.
Methods and Results—Patients ≥50 years of age, with symptomatic HF and left ventricular ejection fraction ≥45%, were 
enrolled in Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) and 
randomized to spironolactone or placebo. Patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ), 
which was the primary HRQL instrument, and EQ5D visual analog scale at baseline, 4 months, 12 months, and annually 
thereafter. McMaster Overall Treatment Evaluation was assessed at 4 and 12 months to assess global change scores. Change 
scores (+SD) were calculated to determine between-group differences, and multivariable repeated-measures models were 
created to identify other factors associated with change scores. Paired KCCQ data were available for 91.7% of 3445 
TOPCAT patients. By 4 months, the mean change in KCCQ was 7.7±16 and mean change in EQ5D visual analog scale was 
4.7±16. Adjusted mean changes in KCCQ for the spironolactone group were significantly better than those for the placebo 
group at 4-month (1.54 better; P=0.002), 12-month (1.35 better; P=0.02), and 36-month (1.86 better; P=0.02) visits. 
No between-group differences in EQ5D visual analog scale change scores or McMaster Overall Treatment Evaluation 
were noted. Older age, obesity, current smoking, New York Heart Association class III/IV, and comorbid illnesses were 
associated with declines in KCCQ scores. Use of spironolactone was an independent predictor of improved KCCQ scores.
Conclusions—In symptomatic HF with preserved ejection fraction patients, use of spironolactone was associated with an 
improvement in HF-specific HRQL. Several modifiable risk factors were associated with HRQL deterioration.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302.   
(Circ Heart Fail. 2016;9:e001937. DOI: 10.1161/CIRCHEARTFAILURE.114.001937.)
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The Treatment of Preserved Cardiac Function Heart 
Failure With an Aldosterone Antagonist (TOPCAT)6 was con-
ducted in 6 countries and enrolled a large number of symptom-
atic HF-PEF patients to test whether spironolactone improved 
outcomes compared with placebo. The trial demonstrated a 
reduction in HF hospitalizations, but no improvement in the 
primary combined end point of cardiovascular mortality, HF 
hospitalizations, or aborted cardiac arrest. A key prespecified 
secondary outcome measure was the impact of spironolactone 
on changes in HRQL.11 The primary objective of this article 
is to provide the detailed analysis of the effect of spironolac-
tone on short- (4 and 12 months) and long-term (>12 months) 
changes in HRQL. A secondary objective is to determine the 
factors associated with changes in HRQL.
Methods
The design, patient characteristics, and primary outcome for TOPCAT 
have been previously published.6,11,12 Briefly, TOPCAT study was 
a multicenter, international, randomized, double-blind, placebo-
controlled trial of spironolactone versus placebo in subjects with 
symptomatic HF-PEF enrolled in United States, Russia, Republic of 
Georgia, Canada, Brazil, and Argentina. Participants were enrolled 
from August 2006 until January 2012. The subjects enrolled in the 
study were ≥50 years of age, with left ventricular ejection fraction 
≥45% and either a hospitalization primarily for the treatment of HF 
within the year before randomization (hospitalization stratum) or an 
elevated natriuretic peptide level within 60 days before randomiza-
tion (natriuretic peptide stratum). Key exclusion criteria included life 
expectancy<3 years, uncontrolled hypertension, constrictive pericar-
ditis, known infiltrative or hypertrophic cardiomyopathy, history of 
serious or unprovoked hyperkalemia, and estimated glomerular filtra-
tion rate <30 mL/min per 1.73 m2. TOPCAT was conducted with the 
approval of local institutional review boards.
Assessment of Quality of Life
Three self-administered questionnaires were used to assess different 
aspects of HRQL: the Kansas City Cardiomyopathy Questionnaire 
(KCCQ)13 for assessing HF-specific HRQL related to HF, the EQ5D 
Visual analog scale (EQ5D-VAS)14 for assessing generic HRQL to 
measure non–HF related perceptions, and the McMaster Overall 
Treatment Evaluation (McMaster OTE) for assessing the individual 
patient’s perception of overall changes in HRQL since the beginning 
of therapy to help quantify change scores.15 The primary HRQL out-
come measure is the KCCQ overall summary score with supportive 
analyses of the other 2 instruments. The KCCQ is a HF-specific 23-
item self-administered questionnaire developed to evaluate HF pa-
tients’ HRQL, symptoms, and function. Domains include physical 
limitation, symptoms (frequency, severity, and change over time), 
quality of life, social limitations, and self-efficacy. Each response is 
given an ordinal value, and scale scores are transformed into a 0 to 
100 range, with higher scores indicating better HRQL. KCCQ has 
been validated in HF populations, including in HF-PEF,16 and is re-
sponsive to important changes in health state.17,18 A clinically mean-
ingful difference in KCCQ score is established as 5 points.18 The 
EQ5D-VAS has 5 items for utility assessment and a single VAS for 
generic HRQL.14 The 5-item utility portion of the EQ-5D was not 
administered to minimize burden to the subjects because cost-effec-
tiveness analysis were not required. Only the single VAS component 
was used, which is a vertical scale from 0 to 100, with 0 represent-
ing the worst possible HRQL and 100 representing the best possible 
HRQL. The EQ5D-VAS has been used in multiple populations, in-
cluding HF,19,20 and a clinically meaningful difference in EQ5D-VAS 
score is established as 5 points.21 The McMaster Overall Treatment 
Evaluation15 is a self-administered 3-item instrument that measures 
the patient’s perception of changes in their HRQL since start of 
therapy. The first question asks if there has been a change in their 
health since treatment began. The subject responds with a check in 1 
of 3 boxes: better, no change, or worse. If either better or worse was 
checked, then the second question asks the subject to rate how much 
better (worse) their condition has changed ranging from a very great 
deal better (worse) to almost the same, hardly better (worse) at all. 
The scores obtained on a Likert scale ranged across 15 points from +7 
to −7, with a score of 0 for subjects who stated no change on question 
1. Question 3 asked “how important is this change (better/worse) to 
you?” on a 7-point scale. These 3 instruments collectively provide an 
overall assessment of the impact of therapy on patients’ HRQL.
The KCCQ and EQ5D-VAS (with appropriate validated transla-
tions in all languages) were given to all participants enrolled in the 
study. The KCCQ and EQ5D-VAS were administered at baseline, 
4 months, 12 months, and then annually until final study visit. The 
McMaster OTE was administered at 4 months and 12 months only for 
subjects in the United States, Canada, and Argentina to ensure valid 
translations of this instrument.
Statistical Analysis
The prespecified primary HRQL outcome measure was the KCCQ 
overall summary score. The outcomes were predefined as changes 
in KCCQ and EQ5D-VAS, and change scores were computed from 
baseline to each study visit occurring at months 4, 12, 24, 36, 48, and 
60 with primary focus on the first 12 months with unadjusted change 
scores created. For each outcome, a backward selection method was 
used to select the baseline covariates, which were significantly as-
sociated with change in outcome at each time point to identify fac-
tors that influence the change scores in addition to randomization. 
Randomized treatment group, randomization stratum, and the base-
line value of the outcome measure were forced into all covariate-
adjusted models. Candidate variables were prespecified. Otherwise, 
nonsignificant variables were not included in final model. Mean 
changes at each time point were compared across the 2 randomized 
treatment groups using analysis of covariance, adjusting for baseline 
outcome value, stratum, and all baseline covariates significant for that 
outcome at ≥1 visit. The impacts of therapy on changes in KCCQ 
and EQ5D-VAS scores over time were examined using a repeated-
measure analysis of covariance (using all follow-up time points). A 
Bonferonni correction was applied to both analysis of covariance 
models given multiple testing as a conservative estimate (P<0.0083 
corrected). Time was treated as a categorical variable (months 4, 12, 
24, 36, 48, and 60), and the interaction term of treatment and time 
was tested to examine whether treatment group effect on change in 
each outcome differed depending on the time point.
The repeated-measures models were also repeated separately 
for subjects in each of the 2 regions (Americas and Eastern Europe) 
given the significant differences in patient characteristics and clini-
cal outcomes in the primary article.6 The impact of randomization 
on change scores was calculated for patients who permanently 
discontinued study drug and those who did not discontinue study 
drug. The proportion of subjects in each treatment arm reporting 
improvement, no change, or decline on the McMaster OTE was cal-
culated. Statistical analyses were performed at the TOPCAT Data 
Coordinating Center at New England Research Institutes (Watertown, 
MA) with SAS Version 9.3 statistical software (SAS Institute) and 
R Version 3.0.2 software (R Foundation for Statistical Computing, 
http://www.r-project.org/) and verified at the Brigham and Women’s 
Hospital. A P<0.05 was considered statistically significant.
Results
The distributions of KCCQ and EQ5D-VAS scores at each 
follow-up visit are presented in Table 1. Of the 3445 patients 
enrolled in TOPCAT, paired baseline and follow-up KCCQ 
data were available for 3158 (91.7%) at 4 months and 
2902 (84.2%) at 12 months. Paired EQ5D-VAS data were 
available for 3149 (91.4%) at 4 months and 2886 (83.8%) 
at 12 months. At 24 months, ≈69% completed KCCQ and 
EQ5D-VAS scores with decreasing responses for subsequent 
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baseline and increased to 62.8±20 by 4 months and 63.8±20 
by 12 months. The mean EQ5D-VAS score was 60.3±17 at 
baseline and increased to 65.3±16 by 4 months and 65.9±17 
by 12 months.
Quality of Life Outcomes
The unadjusted and adjusted mean change (±standard error) 
in KCCQ scores from baseline at each visit are presented by 
treatment group in Figure 1A and 1B. The unadjusted mean 
change improved in both spironolactone and placebo groups 
during follow-up. The adjusted mean change in KCCQ was 
significantly higher in the spironolactone group than in the 
placebo group at month 4 (P=0.002) and month 12 (P=0.02), 
with less consistent differences beyond 12 months. Random-
ization to spironolactone was also associated with improved 
KCCQ clinical scores and KCCQ symptom scores at 4 
months compared with placebo; however, these differences 
did not persist beyond 4 months (Figure I in the Data Supple-
ment). There were no significant treatment group differences 
in the other KCCQ domains (social interference, physical 
scores, quality of life) during follow-up. The unadjusted and 
adjusted mean changes (±standard error) in EQ5D-VAS are 
presented in Figure 2. There was no significant difference 
in mean change in EQ5D-VAS between spironolactone and 
placebo groups at any visit in either the unadjusted or the 
adjusted analyses. There were no significant differences in the 
McMaster OTE perception of change scores at 4 months and 
12 months in patients randomized to spironolactone versus 
placebo (Figure 3).
When evaluating patients on study drug, there were signif-
icant improvements in KCCQ for spironolactone versus pla-
cebo at 4 and 12 months with persistence through 48 months 
(Figure IIA in the Data Supplement). No differences were 
seen in EQ5D-VAS change scores between the groups (Figure 
IIB in the Data Supplement).
Predictors of Longitudinal Changes in KCCQ and 
EQ5D-VAS
In the multivariable repeated-measures model, randomization 
to spironolactone was associated with a 1.36 point additional 
increase in KCCQ scores compared with the change for sub-
jects randomized to placebo, adjusting for all other variables 
(Table 2). Additional predictors of improvements in KCCQ 
scores include hospitalization stratum, living in the Americas 
(as opposed to Russia/Georgia), and taking other cardiovascu-
lar medications. The percentage of meals eaten at home was 
also associated with changes in KCCQ but the effects were 
not linear. Predictors of declines in KCCQ scores include 
New York Heart Association (NYHA) Class III/IV functional 
class, older age, higher baseline KCCQ score, obesity, cur-
rent smoking, use of a hypoglycemic medicine, history of 
chronic obstructive lung disease, bone fractures, hyperten-
sion, and thyroid disease. There was a general upward trend 
in KCCQ changes over time, although the overall test for 
time was not statistically significant (P=0.055). The differ-
ence in mean EQ5D-VAS change between treatment groups 
was 0.467 points, which was not statistically significant 
(P=0.223), and the difference in change in EQ5D-VAS over 
Table 1. Means and Frequencies of KCCQ and EQ5D-VAS Scores at Each Visit
Baseline  
(N=3400)
Month 4  
(N=3190)
Month 12  
(N=2951)
Month 24  
(N=2408)
Month 36  
(N=1792)
Month 48  




















N/A 3158 7.7±15.9 2902 8.2±18.0 2364 8.9±18.5 1762 9.4±19.2 1250 9.9±19.3 807 11.1±20.2
KCCQ 
Categories
  0–25 219 (6.4%) 83 (2.6%) 93 (3.2%) 75 (3.2%) 52 (2.9%) 39 (3.1%) 23 (2.8%)
  26–50 1260 (37.1%) 787 (24.8%) 639 (21.9%) 471 (19.8%) 324 (18.2%) 211 (16.8%) 123 (15.2%)
  51–75 1281 (37.7%) 1416 (44.6%) 1282 (43.9%) 1065 (44.8%) 810 (45.6%) 572 (45.5%) 379 (46.9%)
  76–100 640 (18.8%) 890 (28.0%) 908 (31.1%) 768 (32.3%) 590 (33.2%) 436 (34.7%) 283 (35.0%)




N/A 3149 4.7±16.2 2886 5.0±17.2 2355 5.7±17.9 1756 7.0±17.8 1247 7.8±17.9 803 8.6±18.1)
EQ5D-VAS 
categories
  0–25 100 (2.9%) 51 (1.6%) 43 (1.5%) 35 (1.5%) 21 (1.2%) 19 (1.5%) 7 (0.9%)
  26–50 1134 (33.4%) 707 (22.3%) 650 (22.3%) 499 (21.0%) 336 (19.0%) 228 (18.1%) 145 (18.0%)
  51–75 1582 (46.6%) 1629 (51.4%) 1452 (49.9%) 1154 (48.6%) 866 (48.8%) 604 (48.1%) 361 (44.8%)
  76–100 579 (17.1%) 785 (24.7%) 767 (26.3%) 686 (28.9%) 550 (31.0%) 406 (32.3%) 292 (36.3%)
COPD indicates chronic obstructive lung disease; CV, cardiovascular; EQ5D-VAS, EQ5D visual analog scale; KCCQ, Kansas City Cardiomyopathy Questionnaire; and 
NYHA, New York Heart Association.D
ow
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time was significant (P<0.001), indicating that the average 
change in EQ5D-VAS was increasing over time (Table 3). 
Several predictive variables for KCCQ scores were consistent 
predictors for the EQ5D-VAS change scores, including liv-
ing in the Americas with improved scores and obesity, chronic 
obstructive lung disease, bone fracture, thyroid disease, 
NYHA Class III/IV, and use of a hypoglycemic agent with a 
decline in EQ5D-VAS. Compared with non-Hispanic White 
patients, Black and Hispanic patients noted improvements in 
EQ5D-VAS over time, but not in KCCQ scores. The presence 
of chronic kidney disease and atrial fibrillation were associ-
ated with declines in EQ5D-VAS, but not in KCCQ scores.
Regional Differences in Quality of Life Responses
Given the regional differences between patient characteris-
tics and outcomes between those randomized in the Americas 
versus Russia/Georgia, all key analyses were repeated in both 
regions separately. Patients in the Americas (Table I in the 
Figure 2. Unadjusted (A) and adjusted (B) mean (SE) of change in EQ5D visual analog scale (EQ5D-VAS) from baseline at each visit by 
treatment group.
Figure 1. Unadjusted (A) and adjusted (B) mean (SE) of change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline at 
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Data Supplement) started with a better overall HRQL and had 
a smaller improvement over time than patients in Russia/Geor-
gia (Table II in the Data Supplement). Patients randomized 
to spironolactone in the Americas noted a 2.079±0.74 greater 
improvement in KCCQ compared with placebo patients 
(P=0.005). In contrast, subjects randomized to spironolactone 
in Russia/Georgia noted a 0.654±0.50 greater improvement in 
KCCQ compared to placebo patients (P=0.192). However, the 
interaction term of region and treatment group was not sig-
nificant (P for interaction=0.130). Additional regional simi-
larities and differences are detailed in Figure IIIA and IIIB 
in the Data Supplement. The multivariable models did not 
change dramatically for either KCCQ (Tables III and IV in 
the Data Supplement) or EQ5D-VAS (Tables V and VI in the 
Data Supplement).
Discussion
The management goals of HF-PEF patients continue to 
improve survival, reduce morbidity and hospitalizations, 
attenuate disease progression, and improve HRQL and exer-
cise capacity. Patient’s preferences for the priority of these 
goals are highly individualized.22 Despite the importance of 
HRQL in HF-PEF, limited data exist on the impact of ther-
apies on this important patient-reported outcome.23,24 The 
primary HRQL analysis of TOPCAT demonstrated that spi-
ronolactone use was associated with a statistically significant 
improvement in HRQL using the HF-specific KCCQ driven 
by improvements in symptoms and clinical scores domains. 
However, there was not an improvement in generic HRQL 
based on EQ5D-VAS or in the McMaster OTE, suggesting 
that non–HF related HRQL was not influenced. In a multi-
variable model that adjusted for baseline HRQL and factors 
associated with HRQL, use of spironolactone remained statis-
tically associated with improvements in HRQL using repeated 
measures extending to 60 months.
Improving HRQL in patients with medical therapy has 
historically been difficult given the various factors associ-
ated with change scores, insensitivities of the instruments to 
measure small (but important) differences, and lack of com-
plete data during longer follow-up periods in part because of 
competing risks of death. Use of spironolactone was associated 
with a short-term and long-term difference in KCCQ scores. 
The generic HRQL (measured by EQ5D-VAS) improved in 
both groups without a between-treatment difference. As in 
other publications of TOPCAT with disparate outcomes in 
the Americas and Russia/Georgia,6,25 there were regional dif-
ferences in HRQL responses with significant improvements 
in the Americas. After adjusting for baseline characteristics, 
randomized treatment group, and baseline HRQL values, 
mean changes in KCCQ and EQ5D were significantly better 
for patients from the Americas than for those from Russia/
Georgia. However, the patient characteristics and other pre-
dictors of change scores were similar in the 2 regions.
Several studies have evaluated therapies on HRQL in 
HF-PEF. The Aldosterone Receptor Blockade in Diastolic 
Heart Failure (ALDO-DHF) study randomized 422 patients 
with HF-PEF to spironolactone or placebo, and there was no 
difference in Minnesota Living with Heart Failure (MLHF) 
scores by 12 months.8 The Irbesartan in Heart Failure with 
Preserved Ejection Fraction study (I-PRESERVE) demon-
strated no impact of irbesartan on changes in MLHF scores 
compared with placebo, although both groups noted clinically 
meaningful changes.5 The Phosphodiesterase-5 Inhibition 
to Improve Clinical Status and Exercise Capacity in Heart 
Failure with Preserved Ejection Fraction (RELAX) trial dem-
onstrated no differences in change of HRQL using the MLHF 
questionnaire with median improvements of 8 points in both 
sildenafil and placebo groups.9 Patients receiving candesar-
tan in CHARM-Preserved noted an improvement in overall 
perception of change in their HRQL compared with placebo, 
but impact on MLHF scores has not been reported.26 There is 
more experience with KCCQ in HF-REF populations. Systolic 
Heart Failure Treatment With the If Inhibitor Ivabradine Trial 
(SHIFT) assessed HRQL in HF-REF and demonstrated a 
similar magnitude of improvement in KCCQ scores over 12 
months with a 2.4 point between-group difference between 
ivabradine and placebo.27 Multicenter Automatic Defibrillator 
Implantation Trial With Cardiac Resynchronization Therapy 
(MADIT-CRT) enrolled 1699 patients with NYHA Class I/
II HF and demonstrated improvement in KCCQ of 1.3 points 
Figure 3. Impact of spironolactone vs placebo on 
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better than defibrillator alone and 2 points better in cohort 
with left bundle branch block.28 The Placement of Aortic 
Transcatheter Valve (PARTNERS) trial evaluated transcuta-
neous aortic valve replacement versus surgical aortic valve 
replacement and demonstrated significant improvements 
in KCCQ at 1 month with a 5.5 point difference, but there 
were no differences at 6 or 12 months.29 The addition of sur-
gical ventricular restoration to bypass surgery did not result 
in significant difference between KCCQ change scores in 
comparison to bypass alone in The Surgical Treatment for 
Ischemic Heart Failure (STICH).30 Finally, the magnitude of 
change and between-group differences in TOPCAT was simi-
lar to the magnitude seen with cardiac rehabilitation in the 
Heart failure: a Controlled Trial Investigating Outcomes of 
Exercise Training (HF-ACTION) trial (5.2 versus 3.3 point 
change score in comparison with usual care).31 Thus, the 
noted improvements in HRQL with spironolactone in HF-PEF 
deserve closer evaluation.
Understanding factors that influence future HRQL can be 
important for medical decision making about therapies and 
goals of care, especially as some patients will prefer HRQL as 
the more important outcome.32–34 We identified several factors 
that are associated with declining KCCQ scores during fol-
low-up, including older age, obesity, active smoking, need for 
hypoglycemic agents, NYHA Class III or IV functional capac-
ity, and comorbid illnesses beyond HF. Some of these same 
factors influenced baseline HRQL as well.35 Interestingly, 
despite female sex influencing baseline HRQL,35 this did not 
influence longitudinal change in HRQL and did not make it 
into the final model. Older age and diabetes mellitus are 2 fac-
tors that influenced future declines in HRQL in HF-REF.36 A 
study enrolling 111 HF-REF and HF-PEF patients referred to 
cardiac rehabilitation demonstrated that higher BMI and worse 
NYHA class at baseline were associated with worse HRQL 
over a mean of 2.8 years.37 Smokers had a nonsignificant trend 
toward worse HRQL. The presence of chronic obstructive lung 
disease, thyroid disease, and hypertension may increase anxi-
ety or directly impact symptom burdens with some overlap 
with HF symptoms and could lead to decrements in HRQL. 
The presence of some of these comorbid illnesses may impact 
Table 2. Repeated Measures Model for Changes in KCCQ
Model Covariates
Changes in KCCQ
Estimates (SE) P Value*
Randomization to spironolactone  
(vs placebo) 1.36 (0.44) 0.002
Visit month 0.055†
  12 (vs 4) 0.53 (0.28) 0.057
  24 (vs 4) 0.79 (0.33) 0.017
  36 (vs 4) 0.79 (0.38) 0.038
  48 (vs 4) 1.18 (0.43) 0.006
  60 (vs 4) 1.46 (0.51) 0.004
Baseline KCCQ score  
(per 1 point increase) −0.42 (0.01) <0.001
Hospitalization stratum 1.44 (0.55) 0.009
Americas‡ (vs Russia/Georgia) 2.14 (0.78) 0.006
Age, y −0.08 (0.03) 0.002
Race/ethnicity 0.640†
  Black, non-Hispanic (vs White,  
non-Hispanic) 1.00 (0.98) 0.308
  Hispanic (vs White, non-Hispanic) 0.30 (0.91) 0.742
  Other/missing (vs White, non-Hispanic) −1.37 (1.94) 0.481
Obesity −1.73 (0.48) <0.001
Smoking Status 0.022†
  Current (vs never) −1.82 (0.79) 0.022
  Former (vs never) 0.44 (0.51) 0.390
Atrial fibrillation −1.07 (0.61) 0.077
Angina pectoris −1.17 (0.78) 0.134
Asthma −1.59 (0.96) 0.100
Coronary artery disease −0.71 (0.84) 0.401
Myocardial infarction 0.13 (0.60) 0.832
COPD −2.33 (0.73) 0.002
Bone fracture −1.83 (0.73) 0.012
Hypertension −2.17 (0.81) 0.007
Pacemaker −0.77 (0.90) 0.394
Stroke −1.24 (0.85) 0.144
Thyroid disease −1.40 (0.63) 0.025
Calcium-channel blocker 0.57 (0.46) 0.219
Aspirin −0.49 (0.52) 0.349
Statins −0.53 (0.50) 0.291
Warfarin 0.05 (0.71) 0.948
Hypoglycemic agent −1.56 (0.56) 0.005
Other CV medication§ 1.20 (0.49) 0.014
Cooking salt score 0.00 (0.07) 0.996
Meals at home, % 0.012†
  Almost all (vs None) 1.06 (1.08) 0.326
  75% (vs None) 1.02 (1.19) 0.391
  50% (vs None) 0.00 (1.32) 0.998
  25% (vs None) 5.01 (1.62) 0.002
Living situation 0.092†
  Currently living with spouse/ 
sig other (vs living alone) 1.05 (0.57) 0.066
(Continued )
  Currently living with someone other than 
spouse (vs living alone) −0.16 (0.87) 0.856
NYHA functional class III/IV (vs I/II) −2.13 (0.51) <0.001
The baseline KCCQ score was 54.8. COPD indicates chronic obstructive lung 
disease; CV, cardiovascular; KCCQ, Kansas City Cardiomyopathy Questionnaire; 
and NYHA, New York Heart Association.
*All P values provided are from t tests with exception of those denoted with 
† from Type 3 F-Test. Models contain all covariates that were statistically 
significant across the 6 time points.
‡Americas represent subjects enrolled in United States, Canada, Brazil, or 
Argentina.
§CV medications other than aspirin, calcium-channel blocker, hypoglycemic 
agent, long-acting nitrate, statin, warfarin, diuretic, angiotensin-converting 
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the degree to which a HF-specific intervention can improve 
a patient’s HRQL, and this complex interaction should be 
further elucidated in future research. Interim cardiovascular 
events were not included in the model, and this may provide 
a link between excess comorbid illnesses and more severe HF 
with decrements in HRQL.20 In contrast, few factors improved 
KCCQ scores longitudinally. Randomization to spironolactone 
independently improved KCCQ even after adjusting for all 
important factors. Nevertheless, given the equal impairment in 
HRQL between HF-PEF and HF-REF patients,3 confirmation 
of the factors that influence declines in HRQL is important, 
especially because some of these factors are modifiable.
There are several limitations to this analysis. First, there 
was a dramatic decline in the completion of the HRQL instru-
ments beyond 12- and 24-month visits, which creates a healthy 
cohort effect that may have caused the overall mean HRQL 
scores to improve over time. Moreover, nonfatal events may 
influence these HRQL perceptions. Focus on change scores 
should be within a short time frame as the primary efficacy end 
point for HRQL (eg, 6–8 months) to avoid competing risks of 
death, attrition, and comorbid illnesses. The large sample size 
with 3 distinct measures of HRQL may identify statistically 
significant differences that may not be perceivable by patients. 
However, the a priori determination of KCCQ as the primary 
HRQL measure reduces this concern. Populations in clinical 
trials tend to be healthier than the community-based cohorts, 
and HRQL responses to spironolactone may be different in 
patients who were not eligible for enrollment in TOPCAT. 
Finally, close follow-up and frequent visits may have influ-
enced HRQL beyond the therapy, which may be the reason for 
over 50% of subjects having a clinically meaningful change 
score in the KCCQ in the placebo arm. Nevertheless, this is 
one of the largest studies in HF-PEF assessing HRQL.
In conclusion, stable, symptomatic patients with 
HF-PEF who receive spironolactone note an improvement 
in HF-specific HRQL compared with patients receiving pla-
cebo by 4 months, and this difference is seen ≤36 months. 
The beneficial effects are independent of multiple factors that 
influence patient change scores. Given the relatively small 
magnitude of change scores, further research is required to 
better delineate the potential role of this therapy to improve 
HRQL, an important target of novel interventions in this 
undertreated population.
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intervention.
*All P values provided are from t tests with exception of those denoted with 
† from Type 3 F-Test. Models contain all covariates that were statistically 
significant across the 6 time points.
‡Americas represent subjects enrolled in United States, Canada, Brazil, or 
Argentina.
§CV medications other than aspirin, calcium-channel blocker, hypoglycemic 
agent, long-acting nitrate, statin, warfarin, diuretic, angiotensin converting 
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CLINICAL PERSPECTIVE
This study reports the primary quality of life longitudinal outcomes for the Treatment of Preserved Cardiac Function Heart 
Failure With an Aldosterone Antagonist Trial (TOPCAT), one of the largest trials conducted on patients with heart failure 
with preserved ejection fraction. Given the equally impaired quality of life in this population compared with heart failure 
with reduced ejection fraction, strategies to improve these outcomes are paramount. The relative complete ascertainment 
of quality of life data allowed for rigorous assessments of longitudinal impact of therapy. Patients who were randomized 
to spironolactone noted improved quality of life using the Kansas City Cardiomyopathy Questionnaire in comparison to 
patients receiving placebo. These differences were noted by 4 months and persisted to 36 months. No differences were seen 
with generic measures of quality of life (EQ-5D and McMaster Overall Treatment Evaluation). Independent predictors of 
declines in quality of life included older age, obesity, current smoking, comorbid illnesses, and advanced New York Heart 
Association class III/IV. Some of these reversible factors may be novel targets for improving quality of life in this patient 
population. Moreover, clinicians may consider more careful evaluation of their patients’ quality of life when they have these 
high-risk features because more intensive and focused management may attenuate this progressive decline and may help in 
shared decision making about goals of care. Overall, these results suggest a modest, but statistically significant, improvement 
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